Experimental sickle cell disease drug gets PRIME status
admin 29th June 2017 Uncategorised 0Global Blood Therapeutics’ GBT440 has become the first potential treatment for sickle cell disease to be accepted onto the European Medicines Agency’s regulatory support programme PRIME.
More: Experimental sickle cell disease drug gets PRIME status
Source: News